Discrete Assay for Integrated HPV DNA in Cervical Cells

宫颈细胞中整合 HPV DNA 的离散检测

• 批准号: 6658089
• 负责人: PHILLIP T MOEN
• 金额: $ 39.72万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6658089
• 关键词: cell line; cervix; cervix neoplasms; clinical research; communicable disease diagnosis; cytodiagnosis; diagnosis design /evaluation; female; human papillomavirus; human tissue; in situ hybridization; neoplasm /cancer genetics; neoplastic process; polymerase chain reaction; tissue /cell preparation; virus DNA

DESCRIPTION (provided by applicant): Human papillomavirus (HPV) is implicated as the primary cause of cervical cancer. Although assays that reliably detect HPV are available, their prognostic value for predicting progression to cervical cancer remains controversial, underscoring the need for assays with improved prognostic value. This Phase II SBIR will develop a novel method for detecting integrated HPV DNA in cervical cells. Oncogenic HPV DNA integration into the host genome is a common occurrence in cervical cancers and dysplasias, and assays targeting this event may have high clinical value. Detection of integrated HPV DNA, however, is complicated by the frequent co-existence of episomal viral DNA. Using model cell lines which contain both episomal and integrated HPV DNA, and analytical methods such as in situ hybridization and PCR, Phase I research successfully detected integrated HPV DNA. Phase II research will optimize this approach for use with clinical samples and current liquid-based cytology methods. In contrast to conventional HPV tests, which identify viral types, this assay detects viral integration and targets a wider range of viral types, increasing assay sensitivity. PROPOSED COMMERCIAL APPLICATIONS: This screening method for integrated HPV DNA in cervical cells will facilitate diagnosis of cervical cancer and early treatment, reducing mortality rates.

描述（由申请人提供）： 人乳头瘤病毒（HPV）被认为是宫颈的主要原因 癌症。尽管可以可靠地检测到HPV的测定 预测宫颈癌进展的预后价值仍然存在 有争议的，强调对预后改进的测定的需求 价值。此II阶段SBIR将开发一种用于检测综合的新方法 宫颈细胞中的HPV DNA。致癌性HPV DNA整合到宿主基因组中 是宫颈癌和发育不良的常见发生，并且测定 针对此事件可能具有很高的临床价值。检测集成的HPV 然而，DNA因偶发病毒的频繁共存而变得复杂 脱氧核糖核酸。使用包含偶发和集成的HPV的模型细胞系 DNA和分析方法，例如原位杂交和PCR，I期 研究成功地检测到了综合的HPV DNA。第二阶段研究将 优化与临床样品和当前基于液体的样品一起使用的方法 细胞学方法。与常规的HPV测试相反，鉴定病毒 类型，该测定检测病毒整合并靶向更广泛的病毒 类型，提高测定敏感性。 拟议的商业应用： 宫颈细胞中综合HPV DNA的这种筛查方法将促进宫颈癌和早期治疗的诊断，从而降低死亡率。